Skip to content
Slide thumbnailDrug Development LandscapeONCOLOGYEurope'sDrug Development LandscapeONCOLOGYEurope'sDrug Development LandscapeONCOLOGYEurope's
Slide thumbnailINTELLIGENCEREPORTFirstReleased - June 2024In 24 European CountriesDrug Discovery CompaniesTo Cover 635 Active Oncology635 Oncology
Drug Discovery
Companies
In 24 European
Countries.
Buy NowTable of Contents

635

Region Exclusive Oncology Drug Discovery Companies

First of its kind Report to provide Complete Landscape on Oncology Drug Discovery in Europe Region.

Report Covers Complete Insights on Early Stage Cancer Drug Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

The Europe’s Oncology Drug Development Landscape Market Intelligence Report is designed to Quickly Identify Active Oncology Drug Developers in the region, with their Drug Pipeline, Technologies, Management Expertise, Funding and Partnering capabilities.

Report covers the Largest set of Active Oncology Drug Developers in European Region; with their current late/early stage molecules available for partnering and thus stands out as a perfect market insights partnering and business development tool.

largest coverage Guranteed

providing intelligence at fingertips

Countries
1

24 European Countries’ Covered

Drug developers
1

Oncology Drug Developers Insights

Molecules in Development
200

Individual Drug Mechanism of Action & Drug Target

Cancer Targets
1

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

Prebuild Intelligence

identify Emerging Technologies and Molecules

Molecule Type
The Report Highlights Active Drug Developers Developing
Cellular Therapeutics
89 European Cancer Drug Discovery Companies Developing – CAR-T / CAR-NK & other Cell based Therapies Targeting Cancer.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Monoclonal Antibodies
96 European Cancer Drug Discovery Companies Developing Monoclonal Antibodies against Tumor Antigens.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Bispecific Antibodies &
Bispecific T Cell Engagers
42 European Cancer Drug Discovery Companies Developing Bispecific Antibodies & Bispecific T Cell Engagers.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Antibody Drug Conjugates
42 European Cancer Drug Discovery Companies Developing Antibody Drug Conjugates targeting Cancer.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Cancer Vaccines
65 European Cancer Drug Discovery Companies Developing Vaccines against Cancer.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Kinase Inhibitors
61 European Cancer Drug Discovery Companies Developing Small Molecule Kinase Inhibitors Targeting Cancer
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Targeted Protein Degraders
22 European Cancer Drug Discovery Companies Developing Small Molecule Targeted Protein Degraders against Cancer
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Cancer Targeting Radiopharmaceuticals
22 European Cancer Drug Discovery Companies Developing Cancer Targeting Radiopharmaceuticals.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Oncolytic Viruses
26 European Cancer Drug Discovery Companies Developing Oncolytic Viruses Based Cancer Targeting Drugs.
(Intelligence covering Companies, Technologies & Molecules in Development)
Microbiome & Engineered Bacteria
17 European Cancer Drug Discovery Companies Developing Microbiome & Engineered Bacteria Based Cancer Targeting Drugs
(Intelligence covering Companies, Technologies & Molecules in Development)

intelligence supercharged

956 pages full of Insights

Knowledge Multiplier

Better Than Others

Comparisons
Europe Oncology Drug Development Landscape 2024
Other Intelligence Sources
Active Oncology Drug Developers
635 Active Companies
(Well Funded with clear defined clinical & early stage Pipeline)
250-350 Companies
(with many inactive and other domain companies)
Oncology Drugs in Development
1000+ Onco Targeting Drugs in Active Development
(Complete Clinical & Preclinical Pipeline with indications, Drug Targets and Mechanism of Action)
400 – 600 Cancer Targeting Drugs
(mainly focuses on Clinical Stage molecules)
Bio-Partnering Details
800+ Oncology Deals complete details.
(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation)
Limited to Database / Resource Subscribed to.
(Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals).
Single Step Connect
Over 1500+ Key Decision Makers in 635 Companies
with valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available)
No Customized Solution Available in Market
(Needs months of hard team work to prepare authentic business development tool.

Free Further Customization on This Report

Limited Time Offer  Instand Download

Trusted by

Over 350+ Companies